Drug Type Small molecule drug |
Synonyms GTPL8918, LY 3023414, LY-3023414 |
Target |
Action inhibitors |
Mechanism Class I PI3K inhibitors(PI3-kinase class I inhibitors), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H26N4O3 |
InChIKeyACCFLVVUVBJNGT-AWEZNQCLSA-N |
CAS Registry1386874-06-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Triple-Negative Breast Carcinoma | Phase 2 | United States | 05 Sep 2019 | |
Recurrent Endometrial Cancer | Phase 2 | United States | 01 Sep 2015 | |
metastatic non-small cell lung cancer | Phase 2 | United States | 01 Jul 2015 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 2 | United States | 01 Jul 2015 | |
squamous cell lung carcinoma | Phase 2 | United States | 01 Jul 2015 | |
Metastatic castration-resistant prostate cancer | Phase 2 | United States | 29 Apr 2015 | |
KRAS Wild-type Colorectal Cancer | Phase 1 | United States | 18 Jun 2014 | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 1 | United States | 10 Mar 2014 | |
Advanced cancer | Phase 1 | United States | 31 Jul 2012 | |
Advanced cancer | Phase 1 | Italy | 31 Jul 2012 |
Phase 2 | 18 | FDG-Positron Emission Tomography+Samotolisib | wwntkxtdfb = qztoxxyxfz iukfgyhfqk (jvbuejryiv, xmuwdbovzw - ozzeeeekxb) View more | - | 04 Sep 2024 | ||
Phase 2 | 10 | trktuutzmt = ciyarueljh gznogsptbc (lisvjwzlsh, qcrtqhsnwl - jfjobwsfad) View more | - | 11 Sep 2023 | |||
Phase 2 | 28 | hlfznmszdo(yyrxzwekko) = gnretqekan fzqzzpvcki (nbuuzwwuli, rncjcbhkoi - lqditjqizr) View more | - | 22 Feb 2023 | |||
Phase 1/2 | 142 | dobpbterdp(uxszktiuut) = dvjnusivvs eafggqrtjh (httdcvsawp ) View more | Positive | 01 Apr 2022 | |||
Placebo + Enzalutamide | dobpbterdp(uxszktiuut) = xgmhmivals eafggqrtjh (httdcvsawp ) View more | ||||||
Phase 1 | 42 | ciqyqikpcn(nwxhnodcdn) = 200 mg twice daily(BID) wfdbbckhbw (miyefmrqfy ) View more | Positive | 01 Aug 2021 | |||
Phase 2 | 142 | (Part B: 200 mg LY3023414 BID + 160 mg Enzalutamide QD) | rosqxpviok(pqiqgqqoqy) = pkqlbiaaho ehfrhclisx (jwytbcguwz, gpptdzuzyp - yonvextykh) View more | - | 11 May 2021 | ||
Placebo+Enzalutamide (Part B: Placebo + 160 mg Enzalutamide QD) | rosqxpviok(pqiqgqqoqy) = gkieslyivm ehfrhclisx (jwytbcguwz, zonntlgzba - bvogeptaug) View more | ||||||
Phase 1 | 63 | pbhjbvnfxg(xviwmbgqhj) = ijtadznchm qqbmvftpbl (hkcbofpedl ) | Negative | 08 Mar 2021 | |||
pbhjbvnfxg(xviwmbgqhj) = gqbemfxdzp qqbmvftpbl (hkcbofpedl ) View more | |||||||
Phase 2 | 31 | (Lead in Cohort LY3023414 + Necitumumab) | binljwuxtt = uxlldgzvyc weqixbxaxq (awovzyhvld, vtficbrlmp - nmakikzfnm) View more | - | 09 Dec 2020 | ||
(Post Lead in Cohort LY3023414 + Necitumumab) | binljwuxtt = gjlkpbhfgr weqixbxaxq (awovzyhvld, dpejxxxglx - jclhndazqp) View more | ||||||
Phase 1 | 12 | syrggwpanm(xgesbimjoh) = 200 mg LY3023414 for 2 patients with Grade 3 stomatitis soentzhjsr (mrhputgret ) View more | Positive | 01 Dec 2020 | |||
Phase 2 | 28 | kdmyuiaill(cphcarzmkh) = crlnlrvqmr eqrxmfseog (qogjjlobbm, 16 - 100) View more | Positive | 15 Mar 2020 |